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Background: Breast cancer is a multifactorial disease with the highest incidence rates amongst all cancer types.
Further, high levels of circulating tumour cells are a characteristic of breast cancer patients demonstrating a
particular predisposition to the development of breast cancer metastatic disease. Actual diagnostic approaches are
frequently unable to recognise early stages of tumour development which impairs individual outcomes. In contrast,
predictive and preventive risk assessment and early diagnosis may lead to full recovery after surgical resection.
Recently, the authors have reported about the construction of diagnostic windows, which could influence the
molecular diagnostics of breast cancer.
Material and methods: In a previous study, diagnostic windows for breast cancer risk assessment were analysed.
Women with non-malignant breast diseases demonstrating molecular profiles similar to those of breast cancer
patients were enrolled into this follow-up study. In the interviews, for patients identified as predisposed to cancer, a
specialised questionnaire has been set up to characterise individual risk factors and estimate their potential impacts
on cancer onset and progression.
Results and conclusions: By utilising the technological tool of diagnostic windows, 13 individuals have been
identified demonstrating molecular profiles typical for patients diagnosed with breast cancer. The current paper
summarises the analytical results and makes statements to the application of the pathology-specific molecular
profiles recognised as the technological tool for improved diagnostic approach, breast cancer risk assessment and
preventive health care management. The necessity to create individual patient profiles and analyse the evolution of
the molecular signature is justified for advanced medical services. Expert recommendations are provided to promote
further developments in the field of advanced breast cancer management.
Keywords: Breast cancer risk assessment, Cancer predisposition, Molecular pattern, Economy, Ethics, Predictive
diagnostics, Preventive health careOverview
Breast cancer incidence strongly impacts health, health
care and the economy of medical services
The incidence of breast cancer continually increases world-
wide during the past three decades. Hence, in the USA, the
highest cancer-related incidence rates are currently regis-
tered for breast cancer patient cohorts [1,2]. According to* Correspondence: olga.golubnitschaja@ukb.uni-bonn.de
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reproduction in any medium, provided the orthe statistical data published by the National Cancer Insti-
tute in the USA [3], the estimated new cases and deaths
from breast cancer in the USA in 2012 are as follows (in
thousand cases):
➢ New cases, 226,870 (female); 2,190 (male)
➢ Deaths, 39,510 (female); 410 (male)
Regarding the economy of corresponding medical ser-
vices, in the USA, the costs for prescriptions against breast
cancer create the second leading category of allLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The therapy costs for each patient with metastatic breast
cancer have been reported reaching US$128.556 over a
mean follow-up time of 18 months [5].
Circulating tumour cells are most frequent in breast
cancer amongst all cancer types
The high level of circulating tumour cells (CTC) secondary
to breast cancer onset has been described in the literature
to highly predispose the patient cohort to breast cancer
metastatic disease (BCMD) [6-8]. Consequently, blood tests
are a promising approach for diagnosing BCMD. A further
promising diagnostic approach might be the molecular
characterisation of CTC as the predictor of tumour inva-
siveness and therapy response [9].
Breast cancer metastatic disease is currently incurable
At the time of diagnosis, a great portion of patients with
breast cancer have locally advanced and/or distant meta-
static disease already. Further, 20% to 30% of patients with
early breast cancer will develop relapse with distant me-
tastasis, mainly to the liver, lung, bones and brain [10].
Once breast cancer has turned metastatic, the disease is
recognised as an incurable one: the 5-year survival barrier
will be reached by only 26% of patients treated for BCMD.
Breast cancer metastasises predominantly into the
lymph nodes, bones, lung, skin, brain, and liver [11].
With the poorest prognosis of approximately 80% mor-
tality rate within the first 12 months of diagnosis, brain
metastases represent a devastating category of BCMD.
Advanced imaging technologies are currently consid-
ered as being the most appropriate tool to diagnose
BCMD, to detect primary lesions and to trace distant me-
tastases over the whole body (whole-body imaging). Well-
recognised technologies are the multidimensional and
multimodal ones: CT, MRI, PET, SPECT and ultrasound;
PET and the combined PET/CT are the key tools for
whole-body scanning. However, there are some substantial
clinical deficits which imaging technologies suffer from
[12]. Small-sized metastases in the lymph nodes may be
detected by amplification of the smallest amounts of tran-
scripts produced by BCMD biomarkers such as CK19 and
others. However, a conclusion might be doubtful, due to
untargeted biomarkers, particularly for heterogeneous tu-
mours which is, indeed, the frequent case [12].
Breast cancer risk assessment
Early detection of the tumour has been demonstrated to be
highly beneficial for significantly enhanced therapy efficacy.
Approaching predictive diagnosis may lead to full recovery
after surgical resection. Furthermore, detection of individual
predisposition to breast cancer represents the optimal way
to trigger targeted preventive measures before the clinical
onset and development of the fatal BCMD. Breast cancerrisk assessment is currently extensively under consideration.
In a recently published article, a detailed justification of the
‘molecular patterns in activated leucocytes as the minimally
invasive diagnostic tool for breast cancer risk assessment’
has been provided by the authors [1]. From the facts and
conclusions summarised there, it is getting obvious that the
pathology-specific molecular/expressional patterns in or-
chestrated leucocytes are activated strictly in accordance to
the precancerous/cancer stage. Therefore, if detected in
correlation with the corresponding disease initiation and
progression stage, these patterns in activated leucocytes
might be of high relevance for diagnostic and treatment
purposes.
This consideration led to the idea of creating a minim-
ally invasive approach for breast cancer risk assessment
based on ex vivo blood tests by examination of the specific
molecular/expressional patterns in circulating leucocytes.
Construction of diagnostic windows for minimally
invasive breast cancer risk assessment based on blood
tests
This multimodal approach utilises a combination of con-
ventional analytical methodologies for the creation of
pathology-specific biomarker patterns at complementary
levels of detection, namely:
– Medical imaging (primary tumour, distant
metastasis)
– Sub-cellular/molecular imaging by ‘comet assay’
DNA analysis (risk assessment for general tumour
predisposition)
– Clinical differential proteomics as a ‘gene hunting’
approach for pathology-specific molecular patterns
in blood cells
– Blood metabolomics for quantification of disease-
relevant metabolite patterns
– Quantitative analysis of enzymatic activities in blood
plasma
– Others followed by mathematical modelling of
pathology-specific profiles
The detailed description of the diagnostic windows
constructed for breast cancer risk assessment is provided
in our earlier publications [1,13,14].
The current paper is dedicated to the application of
the constructed diagnostic windows for the breast can-
cer risk assessment in a non-malignant (control) group
of patients recruited at the Department of Gynaecology,
University of Bonn.
Methods
Recruitment of patients and blood sampling
In a previous study, 161 patients proportionally distributed
between two pools: a group with malignancies (invasive
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‘non-malignant controls/benign lesions’ (fibroadenomas,
fibrocystic diseases, lipomas, adenosis and breast traumas;
79 patients), were recruited at the ‘Breast Cancer Research
Centre’, Rheinische Friedrich-Wilhelms-University of Bonn.
According to the diagnosis, the recruited patients were
grouped as follows: benign breast lesions in pre-menopausal
women (group 1, n = 59), benign breast lesions in post-
menopausal women (group 2, n = 20), invasive breast cancer
in pre-menopausal women (group 3, n = 19) and invasive
breast cancer in post-menopausal women (group 4, n = 63).
Blood samples of all patients were taken prior to the applica-
tion of any invasive procedure such as a core needle biopsy
at the Department of Obstetrics and Gynaecology. All
participants were informed about the purpose of the study
and correspondingly signed the ‘consent of the patient’.
All investigations conformed to the principles outlined in
the Declaration of Helsinki and were performed with
permission by the responsible Ethics Committee of the
Medical Faculty, University of Bonn.
Diagnostic windows for breast cancer risk assessment
The construction of the diagnostic windows for breast
cancer risk assessment was the purpose of the previous
study. The detailed description of the technology, as well
as the critical analysis of both its advantages and limi-
tations, is provided in a series of our previous issue-
related publications [1,13,14]. Herewith, we wish to
summarise the entire approach.
Quantitative sub-cellular analysis by comet assay imaging
The comet assay provides a simple and effective method
for evaluation of DNA damage and DNA repair capacity
in single cells such as leucocytes. The principle of the
assay is based upon the ability of DNA fragments to mi-
grate out of the cell under the influence of an electric field.
An evaluation of the ‘comet’ tail shape and DNA frag-
ments migration pattern allows for assessment of DNA
damage and repair capacity. DNA damage is assigned to
four classes based on the visual aspect of the comets, con-
sidering the extent of DNA migration as published earlier
[15]. For breast cancer patients, the disease-specific comet
patterns have been characterised [14] as follows:
– Increased damage to DNA
– Debilitated apoptotic reaction towards increased
DNA damage
– Pathology-specific comet patterns
– Impact of hormonal status on the specificity of
comet patterns amongst breast cancer patients
– Characteristic windows of comet patterns that may
be utilised for breast cancer risk assessment—both
positive (at high risk) and negative (at low risk)
predictionThe constructed comet assay-based diagnostic win-
dows clearly distinguish between the molecular profiles
of tumour and benign patients; therefore, they are con-
sidered for practical application in differential molecular
diagnostics.
Breast cancer-specific protein expression patterns
Clinical differential proteomics performed in our previ-
ous study revealed breast cancer-specific protein expres-
sion patterns [1]. The affected functional groups applied
to the pathology-specific diagnostic windows are the
following:
1. Microfilamental network-associated and cytoskeletal
assembly proteins
2. Cell motility, migration and adhesion
3. Nucleoside/nucleotide turnover and metabolism
4. Protein metabolism (regulatory protein synthesis and




8. Channels, membrane architecture and intercellular
junction proteins
9. Anti-oxidant defence/redox control
10. Detoxification proteins
11. Stress response/protection-related proteins
12. Cell cycle machinery proteins
13. Heat-shock proteins
14. Apoptosis-related proteins/protection against apoptosis
15. Tissue remodelling enzymes
16. Extra-cellular transport and carrier proteins
17. Signal transduction proteins/signalling pathways
18. Longevity/ageing-related proteins
19. Inflammation-related/anti-inflammatory proteins
20. (Breast) cancer-related inhibitors/promoters
21. Cancer invasion and regulators of metastases formation
The complete literature overview considering the func-
tional relevance of the above-summarised protein groups
to cancer development and metastatic diseases is provided
in our recently published review article [1].
Application of the diagnostic windows to the collective of
patients with benign breast lesions
For the group of patients originally diagnosed as being non-
malignant (altogether 79 persons), individual molecular
profiling has been performed and its potential specificity
for breast malignancy has been evaluated utilising the
above-described diagnostic windows. Individual molecular
profiles have combined sub-cellular imaging for DNA qual-
ity (quantitative comet assay) and characterisation of the
stress proteome and microfilamental network-associated
proteins in circulating leucocytes. Integrative bioinformatics
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tients who have demonstrated molecular profiles similar to
those of breast cancer patients were enrolled into the
follow-up study. Data on patient history at the time of ini-
tial blood collection in 2005 or 2006 were obtained from
the original health records. The follow-up was performed
after informed consent.Follow-up examinations
Including criteria
All patients from the pool of non-malignant controls/be-
nign lesions but demonstrating molecular profiles simi-
lar to the profiles of breast cancer patients have been
invited to participate in the follow-up study.Excluding criteria
Patients with malignant breast tumours at the time of
original diagnosis have been excluded from the follow-
up study.Specialised questionnaire
A specialised questionnaire was created in order to col-
lect information which might provide insights into the
reasons of the ‘suspect molecular signature’ in terms of
its high similarity to the molecular profiles characteristic
of the breast cancer patient cohort. Previous and current
data on medical history for each patient and their fam-
ilies were collected using the following questions:1. Did you suffer from any other disease in 2005/2006
(high blood pressure, asthma, chronic pain
syndrome, diabetes, etc.)?
2. Are you currently suffering from any illness that has
not been diagnosed in 2005/2006 but later on?
3. Have you ever been diagnosed cancer?
4. Do your close relatives suffer from cancer or any
other chronic diseases (diabetes, asthma, etc.)?
5. Did you suffer from any kind of stress (familiar,
occupational, etc.) in 2005/2006 or did you suffer
from a high degree of psychological strain due to
uncertainty of the histological results?
6. Did you smoke in 2005/2006?
7. Do you smoke right know?
8. Do you have children?
9. Have you been pregnant in 2005/2006?
10. Are you pregnant?Communication/interviews with patients
Each patient was sent a questionnaire by mail together with
an invitation for the follow-up study to be performed in
our clinic. In case we did not receive any response, patientswere contacted by a phone call, and the form was filled in
by phone interview.Results
Identification of patients with suspect molecular
signature
The technological tool ‘diagnostic windows for minimally
invasive breast cancer risk assessment based on immune
cells profiling’—the previously detailed ‘know-how’ of the
authors [1], is a multimodal approach utilising pathology-
specific biomarker patterns.
In the current study, the two complementary levels of
detection are as follows:
1. Sub-cellular imaging by quantitative (DNA) comet
assay analysis.
2. Differential proteomics of the targeted functional
groups (‘stress proteome’ and microfilamental
network-associated proteins—both highly relevant
for cancer onset and metastatic disease) have been
applied to 79 blood samples (circulating leucocytes)
of non-malignant female patients for individual
profiling and comparative analysis with breast
cancer characteristic patterns.
Altogether, 13 patients have been identified as demon-
strating molecular profiles similar to those of breast can-
cer patients. These selected patients were included into
the follow-up examinations, which was the focus of the
current study.A revision of the original health records: 3 breast
malignancies revised amongst 13 patients with suspect
molecular signature
Consequently, a revision of the originally performed health
records resulted in the awareness that 3 from the 13 pa-
tients demonstrating a suspect molecular signature were
misleadingly enrolled into the group with non-malignant
controls. The patient and tumour characteristics of the
three patients with an invasive breast cancer at the time of
first diagnosis are summarised in Table 1. For the tumour
marker CA15-3 (43.7, 2.0 and 31.1 U/ml), all the patients
demonstrated a negative blood level (by definition, 0–53
U/ml) prior to surgery.
The remaining ten patients were correctly classified as
currently non-malignant ones. Figure 1 provides a pro-
spective diagnosis overview at the time of blood sampling
in the years 2005 and 2006.
Ten patients with a benign histology were invited to
participate in the follow-up study. However, solely seven
patients were able to participate and have returned the
questionnaire or were contacted by a phone call. All seven
patients, who underwent the follow-up breast examination
Table 1 Patient and tumour characteristics of patients with invasive breast cancer at the time of initial diagnosis
Tumour number Age Menopausal stage Histology T N M G ER PR Her2/neu
1 46 Peri-menopausal Invasive ductal breast cancer 1c 0 0 2 Positive Positive Negative
2 42 Pre-menopausal Invasive ductulo-lobular breast cancer 1c 2a 0 3 Positive Positive Negative
3 63 Post-menopausal Invasive ductulo-lobular breast cancer 1c 0 0 2 Positive Negative Negative
ER estrogen receptor, PR progesterone receptor.
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any evidence of malignancy in the breast.Benign breast alterations
The characteristics of patients with a benign breast alter-
ation are summarised in Table 2.Breast tissue inflammation
One 68-year-old patient was diagnosed with a lymphocytic
mastitis non-puerperalis in the histological workup of the
breast biopsy. This patient reported a palpable mass in her
right breast. At the time of biopsy, there was no evidence
of a systemic inflammation.Non-cancerous chronic diseases
In order to reveal further insights into potential effectors
that could have led to an alteration of the molecular signa-
ture, secondary diagnoses were evaluated. Table 3 summa-
rises the secondary diagnoses at the time of initial blood
collection (n = 7). One patient underwent partial
vulvectomy due to vulvar intraepithelial neoplasia grade III
shortly prior to the blood analysis.
In addition, the onset of further secondary diagnoses
in recent years was asked for. It turned out that one of
the healthy patients developed a ‘burnout’ syndrome,
whereas the patient with chronic inflammation got
chronic heart disease due to atherosclerosis. None of the
patients developed a malignancy at the time point of the










Diagnosis at time of the initial blood 
collection
Figure 1 Initial diagnosis at time of the blood sampling in the
years 2005 and 2006.Pregnancy
One 31-year-old patient with fibroadenoma was pregnant
(second trimester) at the time of initial blood collection.
In this benign case, the pregnancy may have caused the al-
teration of the molecular signature.
Familial predisposition to cancer is highly pronounced in
the group selected for the follow-up examination
Since breast malignancy may be associated with a familial
predisposition, a cancer-related family history has been
evaluated for each patient in the selected group. Indeed,
the family predisposition to cancer has been estimated as
significantly higher in the group compared to the general
population, since each patient from the individuals
selected for this study had at least one first- or second-
degree relative with a cancer history. The associated ma-
lignancies are summarised in Table 4. Further, one patient
has been tested positive for BRCA1 specific mutations.
Diabetes history in the family
Since diabetes mellitus is acknowledged as a strong risk
factor for malignancies developed secondary to metabolic
disease, our questionnaire requested for corresponding
information. Consequently, three patients pointed out
that there is a cluster of diabetes type 2 in the family.
Estimation of the stress impacts
Palpable breast alterations cause deep anxiety and stress
reactions of the affected individuals. Pronounced stressTable 2 Characteristics of the patients with non-malignant
breast alterations selected for the follow-up study
Patient number Age Menopausal stage Histology
1 29 Pre-menopausal Fibroadenoma
2 37 Pre-menopausal Fibroadenoma
3 31 Pre-menopausal Fibroadenoma
4 53 Post-menopausal Mastopathia
5 51 Post-menopausal Papilloma
6 43 Pre-menopausal Fibroadenoma
7 51 Post-menopausal Mastopathia
8 68 Post-menopausal Mastitis non-puerperalis
9 39 Pre-menopausal Fibroadenoma
10 44 Pre-menopausal Fibroadenoma







Chronic pain syndrome 1
Vulvar intraepithelial neoplasia grade III 1
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dramatically altered molecular profiles. In order to esti-
mate potential impacts of stress factors, patients have
been asked for their stress-relevant experience and con-
dition at the time point of the original diagnosis/blood
sampling. Patient statements regarding stress condition
and anxiety towards diagnosis are summarised below:
– ‘…fear of having cancer’
– ‘…was afraid of getting breast cancer during my
pregnancy’
– ‘…familial stress and stress at work’
– ‘…occupational stress in the work place’




A strong predisposing risk factor for the cancer-related al-
terations of molecular profiles is smoking which has beenTable 4 Family history regarding cancer
Cancer type Relative Number of
patients

























Glioblastoma Father 1evaluated within current study. At the time of original
diagnosis/blood sampling, one patient used to smoke. At
the time of the follow-up study, nobody from the selected
individuals has changed original smoking habits.
Results interpretation
In recent years, multiple validated biomarkers have
made their way into clinical routine in the field of breast
cancer management [1]. Most of these factors may help
clinicians to get insight into patient outcomes or give
predictive information about optimal therapy regimes.
However, those markers share the similarity of giving in-
formation for women only after the onset of breast
cancer.
Management of breast cancer has a dramatic influence
on health care and economic consequences. In the actual
context of extensive debates concerning increasing costs
of medical services and limited resources to cover health
care costs, new strategies need to be applied towards more
effective breast cancer management. To give an example,
in the USA, the costs for prescriptions against breast can-
cer are the second largest category of all pharmaceutical
sales with enormously increasing rates [4]. The therapy
costs for each patient with metastatic breast cancer have
been reported to be US$128.556 over a mean follow-up
time of 18 months [5], but also the trend towards the de-
tection of earlier breast cancer stages is under discussion
regarding treatment savings. The savings of costs for treat-
ment and palliative care in advanced breast cancer may be
counterbalanced by the high costs of more aggressive initial
treatments and longer follow-up [16,17]. The recommended
screening by clinical breast examination and mammography
is able to detect breast cancer in early stages and has been
shown to reduce mortality [18-20]. Nevertheless, this
screening procedures cause relatively high percentages of
both false-negative and false-positive results that lead either
to undiagnosed malignancy or to overdiagnosis and
overtherapy, respectively [21-23]. Further, a relatively low
tumour size sensitivity, mainly in young women (<50 years)
with dense breast parenchyma, produces a big portion of
scepsis regarding real benefits by mammography screening
[24]. Due to its detection limitations, mammography results
in the correct diagnosis of breast malignancies ranging
from 68% to 90% cases in women aged 50 years and older.
In contrast, the detection sensitivity is much lower in
women aged 40–49 years with estimated detection rates
ranging between 62% and 76% [25]. Likewise, a meta-
analysis of randomised controlled trials showed a decreased
mortality reduction of only 15% in young women (39–49
years) undergoing regular screening by mammography,
compared to 30% in women aged 49–59 years [26].
Therefore, established mammography screening prog-
rammes are mainly addressed to older women (50–69
years) [27]. In addition, screening by mammography is cost
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feasible in most economically developing countries [28].
Thus, the promotion of awareness of early breast cancer
signs and symptoms as well as sole clinical breast examin-
ation remains the only early detection strategies for low-
income and middle-income countries [29].
As demonstrated above, recent studies of our group
led to the creation of diagnostic windows for breast can-
cer risk assessment by molecular profiling and sub-
cellular imaging demonstrating individual predisposition
to breast malignancies [13,14]. This is the next step for-
ward towards predictive medicine. The present findings
suggest that the use of pathology-specific molecular pro-
files is a feasible approach for individualised breast can-
cer prediction. With the current analysis, we have shown
that the suspect molecular signature detected in the
‘control non-malignant group’ was associated with:
1. Breast cancer (3 cases revised for breast cancer from
13 patients with suspect molecular signature)
2. General (breast) cancer predisposition (familial
predisposition to cancer is highly pronounced in the
group selected)
3. A number of risk factors acknowledged as strongly
promoting (breast) cancer development (see data
provided above)
4. Other factors influencing the patient's health and
mind (stress, etc.)
Obviously, the pathology-specific molecular/sub-cellular
profiling approach is a powerful instrument that allows for
more precise examination of the level of individual health
and that of disease predisposition. Large-scale follow-up
studies should be essentially performed in order to:
(a) Evaluate the predictive power of diagnostic windows
applied here
(b) Estimate the scale of potential economical benefits of
the targeted prevention in groups of risk followed by
the creation of innovative economical models for
advanced medical services in breast cancer
management
(c) Elaborate the ethical aspects of individual prediction
(d) Develop the optimal approaches of participative
medicine as an effective form of individualised
predictive medicine versus reactive disease care
(e) Find significant correlations for the above-mentioned
factors or further factors that have not been evaluated
yet
Expert recommendations
Innovation by molecular patient profiling
Further prospective studies are necessary to verify our ini-
tial results in a larger cohort of patients. Such a studycould consist of regular blood analysis in combination
with examinations by medical imaging as well as the sys-
tematic evaluation of personal and health data at several
time points in a group of women with no history of breast
cancer such as patients with benign breast diseases and
healthy individuals with a family history of cancer, etc.
This setting would allow us to get deeper insights into the
marker profile of non-cancerous patients and might help
identify individual factors relevant for pathology develop-
ment. Moreover, specific alterations associated with car-
cinogenesis might be measured at the initiating stages well
suited for targeted preventive measures. This action is in a
good consensus with the new paradigm proposed to shift
health care from reactive to predictive medicine. This ap-
proach may lead to the following promising measures in
advanced breast cancer management:
1. A molecular profile that shifted towards a
pathology-specific signature would justify a need to
take action for a deeper and more targeted breast
imaging resulting in diagnosing non-invasive forms
of breast cancer—the so-called ductal carcinoma in
situ and lobular carcinoma in situ, with excellent
survival rates as recorded worldwide.
2. Estimation of the individual breast cancer risk may
be realistically performed utilising the regular
examination of the molecular profiles. In the case of
negative dynamicity, corrective treatment algorithms
may be created according to the individual risk
factors and affected molecular pathways.Potential economical impacts of molecular diagnostics
Economical burden of breast cancer management are
permanently increasing, negatively impacting the health
care budgets. In contrast, innovative approaches proposed
by the paradigm of Predictive, Preventive and Personalised
Medicine (PPPM) promote an economically more attractive
scenario for investment in health care; however, they should
get carefully analysed through well-designed pilot projects.
The costs related to the blood-based screening linked to
the follow-up diagnostic measures need to be compared
with the existing screening methods by mammography
from viewpoints of health- and economy-related long-term
outcomes. To give an example: A patient is diagnosed
breast cancer at a progressive stage. In this case, the patient
has to undergo surgery, chemotherapy, radiotherapy and
endocrine treatment for several years causing the so-called
direct costs for the overall medical care. However, the in-
direct costs might be even higher, since this patient is not
able to accomplish the work anymore or for a long period
of time and/or not able to achieve a full-time equivalent
becoming strongly handicapped in both professional and
social activities as well as the family-relevant ones.
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Next to the economical impacts, not less important are also
the ethical aspects of the paradigm shift proposed by the
PPPM approaches. Currently, patients come to the clinic
due to palpable masses in the breast or alarming imaging re-
sults. In this paper the results of our analysis demonstrate
that the majority of the interviewed patients strongly suffer
from anxiety in the time frame essential for the biopsy per-
formance and consider this step as extremely stressful. How
will the matter work in the case of providing a predictive
diagnosis? Nobody can answer this question, since psycho-
logical treatment approaches are completely underdeveloped
in the new field of predictive medicine. Especially, the ethical
aspects of participative (tight and harmonic collaboration
between patient and treating person/s) medicine is a delicate
field which is highly relevant for the overall success in health
and disease management. The corresponding principles of
PPPM ethics should be thoroughly elaborated and approved
under controlled conditions in multidisciplinary studies.Outlook
Predictive medicine is an innovative approach towards a
new era in breast cancer prevention. Breast cancer risk as-
sessment aims at detection of pre-malignant stages that will
revolutionise breast cancer management as a whole from
the viewpoint of the professional set-up, treatment regi-
mens, life quality of a patient, economy and ethics of med-
ical care. The authors are aware of potential risks linked to
any paradigm shifting. Medical care being conservative by
definition, on the other side, should essentially progress to-
wards reasonable innovation benefiting patients and health
care as a whole. The authors intend to follow the above-
justified strategy by setting up large-scale projects with the
relevant multidisciplinary expertise to approve the feasibility
and credibility of PPPM-related innovation in breast cancer
management.
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